• Seikagaku posted Q1 net sales of JPY 8.83 billion, up 1.2% year on year, while operating loss widened to JPY 943 million.
• Ordinary income swung to JPY 108 million from a loss, helped by investment securities sales; net loss attributable to owners narrowed to JPY 11 million.
• Pharmaceutical segment sales fell 7.7% to JPY 5.45 billion as overseas pharmaceuticals dropped 45.9% to JPY 1.05 billion.
• LAL segment sales climbed 19.7% to JPY 3.39 billion on strong overseas demand for endotoxin-detecting reagents and Fungitell.
• Full-year forecast was unchanged, targeting net sales of JPY 41.85 billion and net income attributable to owners of parent of JPY 2.25 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seikagaku Corporation published the original content used to generate this news brief on August 05, 2026, and is solely responsible for the information contained therein.